GBP112.54
1.42% yesterday
London, Mar 31, 05:38 pm CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Stock price

GBP112.54
-7.14 5.97% 1M
-1.68 1.47% 6M
+9.36 9.07% YTD
+7.94 7.59% 1Y
+17.50 18.41% 3Y
+48.26 75.08% 5Y
+78.77 233.30% 10Y
London, Closing price Mon, Mar 31 2025
-1.62 1.42%
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

Key metrics

Market capitalization GBP177.02b
Enterprise Value GBP196.76b
P/E (TTM) P/E ratio 32.08
EV/FCF (TTM) EV/FCF 24.46
EV/Sales (TTM) EV/Sales 4.65
P/S ratio (TTM) P/S ratio 4.18
P/B ratio (TTM) P/B ratio 5.44
Dividend yield 2.15%
Last dividend (FY24) GBP2.46
Revenue growth (TTM) Revenue growth 14.82%
Revenue (TTM) Revenue GBP42.31b
EBIT (operating result TTM) EBIT GBP8.54b
Free Cash Flow (TTM) Free Cash Flow GBP8.05b
Cash position GBP4.51b
EPS (TTM) EPS GBP3.56
P/E forward 23.55
P/S forward 4.00
EV/Sales forward 4.44
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

28x Buy
85%
5x Hold
15%

Analyst Opinions

33 Analysts have issued a AstraZeneca forecast:

Buy
85%
Hold
15%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
42,307 42,307
15% 15%
100%
- Direct Costs 11,739 11,739
18% 18%
28%
30,568 30,568
14% 14%
72%
- Selling and Administrative Expenses 7,246 7,246
13% 13%
17%
- Research and Development Expense 9,556 9,556
16% 16%
23%
13,767 13,767
33% 33%
33%
- Depreciation and Amortization 5,225 5,225
20% 20%
12%
EBIT (Operating Income) EBIT 8,542 8,542
43% 43%
20%
Net Profit 5,515 5,515
15% 15%
13%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Positive
Investors Business Daily
about 8 hours ago
AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. The results could buoy AstraZeneca stock.
Neutral
PRNewsWire
5 days ago
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, South Korea , March 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a deep learning study on Epiderma...
Positive
Proactive Investors
7 days ago
AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) remain among Berenberg's top picks in the pharmaceuticals sector, with the broker reaffirming its 'buy' rating on both stocks. The former carries a target price of £140, while the valuation for stock in the latter is £16.
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 94,300
Founded 1992
Website www.astrazeneca.co.uk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today